$ACIU

AC Immune SA

AC Immune is a clinical-stage biopharmaceutical company developing medicines and diagnostic tools for neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease. It uses its SupraAntigen platform to develop biologic and immunotherapy candidates, and its Morphomer platform to develop small molecules and PET imaging agents. Its programs target proteins including amyloid beta, Tau, alpha-synuclein, NLRP3 and TDP-43. Products and candidates include active immunotherapies, monoclonal antibodies, small-molecule drugs and imaging agents intended to support diagnosis and patient selection. AC Immune makes money through collaboration and licensing agreements with pharmaceutical partners, which can provide payments and royalties, and may advance some candidates independently. Its registered office and domicile are in Ecublens, Switzerland, at the EPFL Innovation Park.

No enriched coverage for $ACIU in the last 7 days.

No SEC Form 4 filings for $ACIU in the last 30 days.

See all $ACIU insider activity →
Low

AC Immune: Q3 Earnings Snapshot

AC Immune SA reported a Q3 loss of $10.8 million, or 16 cents per share, with revenue of $4 million. Shares closed at $2.09, down from $3.18 a year ago, according to the company.

AC Immune Posts Strong Week-100 Phase 2 Data for Parkinson’s Vaccine ACI-7104

AC Immune (ACIU) reported positive week-100 data from Part 1 of its Phase 2 trial for Parkinson's vaccine ACI-7104, meeting safety, tolerability, and immunogenicity endpoints. All patients showed an antibody response, with data suggesting target engagement. The company plans to extend Part 1 and finalize Part 2 design to test clinical efficacy.

ACIU sentiment & insider activity

Recent ACIU coverage spans technology, earnings and regulation.

What's driving ACIU

AlphAI scores every news story that mentions ACIU with an AI model for sentiment and relevance, and aggregates insider trades from AC Immune SA's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ACIU

Score
$ACIUMedAI 8/10

AC Immune stock gains on early Phase 1 trial results

AC Immune SA (ACIU) shares rose 3.9% premarket after reporting positive Phase 1 trial data for ACI-19764, an NLRP3 inhibitor. The drug was safe, well-tolerated, and showed brain penetration. Phase 1b results are expected by year-end, with full results in 2027. ACI-19764 targets chronic inflammation in various diseases.

$ACIUMedAI 8/10

Why is AC Immune stock gaining today?

AC Immune (ACIU) shares rose 3.4% pre-open after the FDA granted Fast Track status to its ACI-7104 anti-alpha-synuclein therapy and cleared its IND. The move allows Phase 2 VacSYn trial enrollment to expand to U.S. sites. Interim 76-week Part 1 data showed a favorable safety profile. The stock was near $2.37.

$ACIUMedEarnings

AC Immune SA (ACIU): Financial results for H1 2026

AC Immune SA (ACIU) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 ​ ​ ​ ​ PRESS RELEASE AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments ​ ● Key advances across pipeline, with further near-term

Related tickers